Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

Research output: Contribution to journalReview article

Standard

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. / Kyle, R. A.; Durie, B. G. M.; Rajkumar, S. V.; Landgren, O.; Blade, J.; Merlini, G.; Kroeger, N.; Einsele, H.; Vesole, D. H.; Dimopoulos, M.; San Miguel, J.; Avet-Loiseau, H.; Hajek, R.; Chen, W. M.; Anderson, K. C.; Ludwig, H.; Sonneveld, P.; Pavlovsky, S.; Palumbo, A.; Richardson, P. G.; Barlogie, B.; Greipp, P.; Vescio, R.; Turesson, Ingemar; Westin, J.; Boccadoro, M.

In: Leukemia, Vol. 24, No. 6, 2010, p. 1121-1127.

Research output: Contribution to journalReview article

Harvard

Kyle, RA, Durie, BGM, Rajkumar, SV, Landgren, O, Blade, J, Merlini, G, Kroeger, N, Einsele, H, Vesole, DH, Dimopoulos, M, San Miguel, J, Avet-Loiseau, H, Hajek, R, Chen, WM, Anderson, KC, Ludwig, H, Sonneveld, P, Pavlovsky, S, Palumbo, A, Richardson, PG, Barlogie, B, Greipp, P, Vescio, R, Turesson, I, Westin, J & Boccadoro, M 2010, 'Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management', Leukemia, vol. 24, no. 6, pp. 1121-1127. https://doi.org/10.1038/leu.2010.60

APA

CBE

Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, Kroeger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M. 2010. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 24(6):1121-1127. https://doi.org/10.1038/leu.2010.60

MLA

Vancouver

Author

Kyle, R. A. ; Durie, B. G. M. ; Rajkumar, S. V. ; Landgren, O. ; Blade, J. ; Merlini, G. ; Kroeger, N. ; Einsele, H. ; Vesole, D. H. ; Dimopoulos, M. ; San Miguel, J. ; Avet-Loiseau, H. ; Hajek, R. ; Chen, W. M. ; Anderson, K. C. ; Ludwig, H. ; Sonneveld, P. ; Pavlovsky, S. ; Palumbo, A. ; Richardson, P. G. ; Barlogie, B. ; Greipp, P. ; Vescio, R. ; Turesson, Ingemar ; Westin, J. ; Boccadoro, M. / Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. In: Leukemia. 2010 ; Vol. 24, No. 6. pp. 1121-1127.

RIS

TY - JOUR

T1 - Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

AU - Kyle, R. A.

AU - Durie, B. G. M.

AU - Rajkumar, S. V.

AU - Landgren, O.

AU - Blade, J.

AU - Merlini, G.

AU - Kroeger, N.

AU - Einsele, H.

AU - Vesole, D. H.

AU - Dimopoulos, M.

AU - San Miguel, J.

AU - Avet-Loiseau, H.

AU - Hajek, R.

AU - Chen, W. M.

AU - Anderson, K. C.

AU - Ludwig, H.

AU - Sonneveld, P.

AU - Pavlovsky, S.

AU - Palumbo, A.

AU - Richardson, P. G.

AU - Barlogie, B.

AU - Greipp, P.

AU - Vescio, R.

AU - Turesson, Ingemar

AU - Westin, J.

AU - Boccadoro, M.

PY - 2010

Y1 - 2010

N2 - Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein < 15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years. Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months. Leukemia (2010) 24, 1121-1127; doi:10.1038/leu.2010.60; published online 22 April 2010

AB - Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein < 15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years. Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months. Leukemia (2010) 24, 1121-1127; doi:10.1038/leu.2010.60; published online 22 April 2010

KW - MGUS

KW - International Myeloma Working Group

KW - myeloma

KW - monoclonal gammopathy of undetermined significance

KW - smoldering multiple

U2 - 10.1038/leu.2010.60

DO - 10.1038/leu.2010.60

M3 - Review article

VL - 24

SP - 1121

EP - 1127

JO - Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

T2 - Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

JF - Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

SN - 1476-5551

IS - 6

ER -